Tralokinumab cohort 2 ( DrugBank: Tralokinumab )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
85	Idiopathic interstitial pneumonia	2

85. Idiopathic interstitial pneumonia

---

Clinical trials : 627 /  Drugs : 443 - (DrugBank : 120) / Drug target genes : 99 - Drug target pathways : 212

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02036580 (ClinicalTrials.gov)	January 2014	13/1/2014	D2212C00002 J-Phase II Study	A Phase 2, Multicenter, Double-Blind Within Cohort, Dose-escalation Study to Evaluate the Safety and Tolerability of Multiple Doses of CAT-354 (Tralokinumab) in Japanese Patients With Idiopathic Pulmonary Fibrosis	Idiopathic Pulmonary Fibrosis	Biological: tralokinumab cohort 1;Biological: tralokinumab cohort 2;Other: Placebo	AstraZeneca	MedImmune LLC	Completed	50 Years	N/A	All	37	Phase 2	Japan
2	JPRN-JapicCTI-142452		21/02/2014	A Phase 2, Multicenter, Double-Blind Within Cohort, Dose-escalation Study to Evaluate the Safety and Tolerability of Multiple Doses of CAT-354 (Tralokinumab) in Japanese Patients With Idiopathic Pulmonary Fibrosis	A Phase 2, Multicenter, Double-Blind Within Cohort, Dose-escalation Study to Evaluate the Safety and Tolerability of Multiple Doses of CAT-354 (Tralokinumab) in Japanese Patients With Idiopathic Pulmonary Fibrosis	Idiopathic Pulmonary Fibrosis	Intervention name : Tralokinumab is a human recombinant monoclonal antibody (MAb) of the subclass that specifically binds human IL-13, blocking interactions with the IL-13 receptor Dosage And administration of the intervention : Low Dose, Biological: tralokinumab cohort 1, High Dose, Biological: tralokinumab cohort 2	AstraZeneca	MedImmune LLC		50		BOTH		Phase 2	NULL